IGHE and ovarian carcinoma: We studied the case of a 75‐year‐old patient with HGS ovarian cancer with a history of COPD and pulmonary embolism, but no allergies or infusion reactions, who received the highest dose levels of MOv18 IgE (3 weekly 6 mg infusions, escalated to 3 weekly 12 mg infusions) (Patient A).